These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33969175)

  • 1. Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease.
    Aschenbrenner AJ; Baksh RA; Benejam B; Beresford-Webb JA; Coppus A; Fortea J; Handen BL; Hartley S; Head E; Jaeger J; Levin J; Loosli SV; Rebillat AS; Sacco S; Schmitt FA; Thurlow KE; Zaman S; Hassenstab J; Strydom A
    Alzheimers Dement (Amst); 2021; 13(1):e12184. PubMed ID: 33969175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease.
    Langbaum JB; Ellison NN; Caputo A; Thomas RG; Langlois C; Riviere ME; Graf A; Lopez Lopez C; Reiman EM; Tariot PN; Hendrix SB
    Alzheimers Res Ther; 2020 May; 12(1):66. PubMed ID: 32460855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.
    Ayutyanont N; Langbaum JB; Hendrix SB; Chen K; Fleisher AS; Friesenhahn M; Ward M; Aguirre C; Acosta-Baena N; Madrigal L; Muñoz C; Tirado V; Moreno S; Tariot PN; Lopera F; Reiman EM
    J Clin Psychiatry; 2014 Jun; 75(6):652-60. PubMed ID: 24816373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.
    Langbaum JB; Hendrix SB; Ayutyanont N; Chen K; Fleisher AS; Shah RC; Barnes LL; Bennett DA; Tariot PN; Reiman EM
    Alzheimers Dement; 2014 Nov; 10(6):666-74. PubMed ID: 24751827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aging related cognitive changes associated with Alzheimer's disease in Down syndrome.
    Firth NC; Startin CM; Hithersay R; Hamburg S; Wijeratne PA; Mok KY; Hardy J; Alexander DC; ; Strydom A
    Ann Clin Transl Neurol; 2018 Jun; 5(6):741-751. PubMed ID: 29928657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Association between Physical Activity and CAMDEX-DS Changes Prior to the Onset of Alzheimer's Disease in Down Syndrome.
    Pape SE; Baksh RA; Startin C; Hamburg S; Hithersay R; Strydom A
    J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33925348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The LonDownS adult cognitive assessment to study cognitive abilities and decline in Down syndrome.
    Startin CM; Hamburg S; Hithersay R; Davies A; Rodger E; Aggarwal N; Al-Janabi T; Strydom A
    Wellcome Open Res; 2016 Nov; 1():11. PubMed ID: 28018980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validating the Cognitive Scale for Down Syndrome (CS-DS) to Detect Longitudinal Cognitive Decline in Adults With Down Syndrome.
    Startin CM; Lowe B; Hamburg S; Hithersay R; Strydom A;
    Front Psychiatry; 2019; 10():158. PubMed ID: 31057430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.
    Wilcock D; Jicha G; Blacker D; Albert MS; D'Orazio LM; Elahi FM; Fornage M; Hinman JD; Knoefel J; Kramer J; Kryscio RJ; Lamar M; Moghekar A; Prestopnik J; Ringman JM; Rosenberg G; Sagare A; Satizabal CL; Schneider J; Seshadri S; Sur S; Tracy RP; Yasar S; Williams V; Singh H; Mazina L; Helmer KG; Corriveau RA; Schwab K; Kivisäkk P; Greenberg SM;
    Alzheimers Dement; 2021 Apr; 17(4):704-715. PubMed ID: 33480172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's polygenic risk scores are associated with cognitive phenotypes in Down syndrome.
    Gorijala P; Aslam MM; Dang LT; Xicota L; Fernandez MV; Sung YJ; Fan KH; Feingold E; Surace EI; Chhatwal JP; Hom CL; ; ; Hartley SL; Hassenstab J; Perrin RJ; Mapstone M; Zaman SH; Ances BM; Kamboh MI; Lee JH; Cruchaga C
    Alzheimers Dement; 2024 Feb; 20(2):1038-1049. PubMed ID: 37855447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex-specific composite scales for longitudinal studies of incipient Alzheimer's disease.
    Banks SJ; Shifflett B; Berg JL; Sundermann E; Peavy G; Bondi MW; Edland SD
    Alzheimers Dement (N Y); 2019; 5():508-514. PubMed ID: 31650007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive Function during the Prodromal Stage of Alzheimer's Disease in Down Syndrome: Comparing Models.
    Hom CL; Kirby KA; Ricks-Oddie J; Keator DB; Krinsky-McHale SJ; Pulsifer MB; Rosas HD; Lai F; Schupf N; Lott IT; Silverman W
    Brain Sci; 2021 Sep; 11(9):. PubMed ID: 34573242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome.
    Startin CM; Hamburg S; Hithersay R; Al-Janabi T; Mok KY; Hardy J; ; Strydom A
    Alzheimers Dement; 2019 Feb; 15(2):245-257. PubMed ID: 30503169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising outcome measures of early Alzheimer's dementia in adults with Down syndrome.
    Krinsky-McHale SJ; Zigman WB; Lee JH; Schupf N; Pang D; Listwan T; Kovacs C; Silverman W
    Alzheimers Dement (Amst); 2020; 12(1):e12044. PubMed ID: 32647741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theoretical exploration of the neural bases of behavioural disinhibition, apathy and executive dysfunction in preclinical Alzheimer's disease in people with Down's syndrome: potential involvement of multiple frontal-subcortical neuronal circuits.
    Ball SL; Holland AJ; Watson PC; Huppert FA
    J Intellect Disabil Res; 2010 Apr; 54(4):320-36. PubMed ID: 20202073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.
    Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D
    J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Sensitivity and Specificity of Cognitive Tests for Mild Cognitive Impairment and Alzheimer's Disease in Patients with Down Syndrome: A Systematic Review and Meta-Analysis.
    Nadeau PA; Jobin B; Boller B
    J Alzheimers Dis; 2023; 95(1):13-51. PubMed ID: 37522203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Cognitive Composite for Preclinical Alzheimer's Disease in Korean Older Adults.
    Kim M; Yi D; Byun MS; Ahn H; Jung JH; Kong N; Chang Y; Choi H; Choi J; Kim K; Jung G; Lee DY;
    J Alzheimers Dis; 2023; 96(2):633-641. PubMed ID: 37807780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening over Speech in Unselected Populations for Clinical Trials in AD (PROSPECT-AD): Study Design and Protocol.
    König A; Linz N; Baykara E; Tröger J; Ritchie C; Saunders S; Teipel S; Köhler S; Sánchez-Benavides G; Grau-Rivera O; Gispert JD; Palmqvist S; Tideman P; Hansson O
    J Prev Alzheimers Dis; 2023; 10(2):314-321. PubMed ID: 36946458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
    Biel D; Luan Y; Brendel M; Hager P; Dewenter A; Moscoso A; Otero Svaldi D; Higgins IA; Pontecorvo M; Römer S; Steward A; Rubinski A; Zheng L; Schöll M; Shcherbinin S; Ewers M; Franzmeier N;
    Alzheimers Res Ther; 2022 Nov; 14(1):166. PubMed ID: 36345046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.